Does Calcium Fracture Randomized Trial work?

Updated June 2026

Quick Answer

Calcium Fracture Randomized Trial has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: Summary This review summarizes current evidence on scoring balloons, cutting balloons, and ultra-high-pressure (OPN NC) balloons and aims to define their specific role and indications in the treatment of calcified coronary disease.

Key Takeaways

  • 01Summary This review summarizes current evidence on scoring balloons, cutting balloons, and ultra-high-pressure (OPN NC) balloons and aims to define their specific role and indications in the treatment of calcified coronary disease. [Colletti G (2026)]
  • 02Background Calcified coronary lesions are a major challenge in percutaneous coronary intervention (PCI), frequently leading to stent underexpansion, restenosis, and adverse events. [Colletti G (2026)]
  • 03While multiple technologies exist for plaque modification, there remains a critical need for clear guidance on the optimal selection and use of dedicated balloon-based devices. [Colletti G (2026)]
  • 04Accordingly, contemporary guidelines no longer recommend IN-CAL as first-line treatment for chronic osteoporosis, and concerns regarding a potential malignancy signal further limited long-term use. [Ahmad Areeb (2026)]
The current Migaku evidence database contains 2 reusable source documents for Calcium Fracture Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove. - Summary This review summarizes current evidence on scoring balloons, cutting balloons, and ultra-high-pressure (OPN NC) balloons and aims to define their specific role and indications in the treatment of calcified coronary disease. [Colletti G (2026); evidence level 3] - Background Calcified coronary lesions are a major challenge in percutaneous coronary intervention (PCI), frequently leading to stent underexpansion, restenosis, and adverse events. [Colletti G (2026); evidence level 3] - While multiple technologies exist for plaque modification, there remains a critical need for clear guidance on the optimal selection and use of dedicated balloon-based devices. [Colletti G (2026); evidence level 3] - Accordingly, contemporary guidelines no longer recommend IN-CAL as first-line treatment for chronic osteoporosis, and concerns regarding a potential malignancy signal further limited long-term use. [Ahmad Areeb (2026); evidence level 3] - 18 A landmark review by Plosker and McTavish summarized the pharmacologic and clinical evidence for IN-CAL through the mid-1990s. [Ahmad Areeb (2026); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. Calcium modifying dedicated balloons: a contemporary review.
  2. Revisiting Intranasal Salmon Calcitonin: Historical Osteoporosis Evidence and a Potential Role in Acute Orthopaedic Pain Management